6533b82bfe1ef96bd128d775
RESEARCH PRODUCT
Matrix metalloproteinases production in malignant pleural effusions after talc pleurodesis
Francesco ArcoleoP. MoceoEnrico CillariPietro D'agostinoE. SaccoRoberto CarusoT. Di RosaA. CascioA. Rao CamemiA. DolceG. Cangemisubject
MalePathologymedicine.medical_specialtyPleural effusionmedicine.medical_treatmentImmunologyMatrix metalloproteinaseTalcStatistics NonparametricClinical StudiesHumansImmunology and AllergyMedicineLung cancerPleurodesisAgedTissue Inhibitor of Metalloproteinase-1business.industryTalc pleurodesisA proteinPlasminogenMiddle Agedmedicine.diseaseMatrix MetalloproteinasesPleural Effusion MalignantC-Reactive ProteinMatrix Metalloproteinase 9Talcalpha 1-AntitrypsinImmunologyPleural fluidFemaleMatrix Metalloproteinase 1businessPleurodesismedicine.drugdescription
SUMMARY In this study we have evaluated the modifications of matrix metalloproteinases (MMPs) in malignant pleural fluids taken from patients suffering from lung cancer and treated with intrapleural talc instillation to induce pleurodesis. Furthermore, we have analysed the variations of some inflammatory mediators (C-reactive protein, α-1 antitrypsin) and of a protein (plasminogen) involved in MMP activation. In all patients the clinical improvement after talc pleurodesis was followed by a reduction in MMP-1, TIMP-1, C-reactive protein, α-1 antitrypsin and plasminogen activity. Furthermore, MMP-9 levels were variable; in fact, in some patients they were high at the beginning of treatment, in others they increased a few days after pleurodesis induction. These inhibitory effects of talc on MMP-1 and inflammatory mediators associated with the reduction of pleural effusion could constitute an effective means to evaluate the evolution of the treatment.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2003-09-17 | Clinical and Experimental Immunology |